for the treatment of overactive bladder (OAB).This is the first time that CTAF has addressed this topic.

For the first time in over 25 years (since the approval of oxybutynin in 1972), better medications are available for the overactive bladder. With the recent approval of tolterodine and oxybutynin ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), today announced the first patient has been randomized and dosed in a Phase 2 clinical study evaluating sunobinop ...

Bayer says its drug candidate for chronic cough – eliapixant ... Other potential indications include endometriosis, overactive bladder and neuropathic pain, and Bayer is also running phase ...

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product. Anktiva (nogapendekin ...

Oct. 15, 2024 — A team tests the protective effect of a fermented black garlic extract against inflammation and the progression of prostate cancer in a study conducted on human prostate cancer ...

Oct. 9, 2024 — A new study has found some cancers to be slightly more frequent in people with multiple sclerosis (MS) than in people without MS. Types of cancers found to have a small increased ...

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...

It is clearly effective in increasing bladder capacity, but the impacts on bedwetting are less certain with mixed results in research studies. It might be a useful adjunctive therapy to other ...

After hours: November 15 at 7:55 PM EST Loading Chart for DRUG ...